Maegim한국어

일성아이에스

003120KOSPISector: Pharma & Biotech
₩20,200▲ 0.75%Market cap ₩268.7BAs of Jul 21, 2026 close · updated once daily
B
Grade B61.9 ptsTop 29% of 2,523 stocks
Financial strength
73.8
Growth momentum
34.0
Price attractiveness
68.1

As of Jul 21, 2026 close · This grade is not a buy/sell recommendation — it is information mechanically scored from public data using a fixed formula.

1

Financial strength

73.8
How much debt does it carry relative to equity?
Debt-to-equity ratio
4.3%
✓ Above median · Top 3% in sector
Sector median 51.5%
Can it cover what's due within a year?
Current ratio
1746.9%
✓ Above median · Top 6.7% in sector
Sector median 191.3%
How much of revenue becomes profit?
Operating margin
-9.6%
✗ Below median · Top 53.7% in sector
Sector median -2.3%
How much did it earn on its own capital?
ROE (return on equity)
0.3%
✓ Above median · Top 41.3% in sector
Sector median -4.5%

Source filing: annual report (separate) — view original ↗

2

Growth momentum

34.0
How much did revenue grow in a year?
Revenue growth (YoY)
-6.8%
✗ Below median · Top 77.9% in sector
Sector median 6.4%
Has it grown steadily over three years?
Revenue 3-year CAGR
1.6%
✗ Below median · Top 64% in sector
Sector median 4.9%
Did core profits grow in a year?
Operating income change (YoY)
35.3%
✓ Above median · Top 26.6% in sector
Sector median 3.6%
Are core profits higher than three years ago?
Operating income change (3Y)
-574.9%
✗ Below median · Top 95.4% in sector
Sector median 3.5%

Source filing: annual report (separate) — view original ↗

3

Price attractiveness

68.1
Is the price expensive relative to earnings?
P/E (price-to-earnings)
230.5x
✓ Above median · Top 39.6% in sector
Sector median P/E of profitable peers 14.4x · 57% loss-making
Is the price expensive relative to book value?
P/B (price-to-book)
0.70x
✓ Above median · Top 24.2% in sector
Sector median 1.39x

Valuation uses the Jul 21, 2026 close and market cap

Grade distribution of 248 stocks in Pharma & Biotech

S1A52B66C51D61F15